Recent Winners On GuerillaStockTrading

Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
Alert Price: $7.17
High Price: $8.24
Results: 15% in 6 Days
Alert Price: $8.49
High Price: $9.55
Results: 12% in 7 Days
Alert Price: $19.50
High Price: $21.93
Results: 12% in 26 Days
Alert Price: $20.00
High Price: $22.42
Results: 12% in 26 Days
Alert Price: $48.15
High Price: $52.90
Results: 10% in 14 Days
Alert Price: $67.61
High Price: $73.56
Results: 9% in 12 Days
Alert Price: $19.94
High Price: $20.75
Results: 4% in 13 Days
Alert Price: $31.53
High Price: $32.69
Results: 4% in 9 Days
Alert Price: $14.05
High Price: $14.55
Results: 4% in 21 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.


Top Catalysts For The Week Ending January 20 2017

Sanchez Energy = Eagleford Acquisition Doubles Drilling Inventory

Mobileye = Goldman Sachs Raised Mobileye To A Buy Rating

Tesla = Expanding Investment In Gigafactory by $350 Million, Adding 550 New Jobs To Make Model 3

AbbVie = Gets FDA Approval For Imbruvica

3D Systems = Hearing Takeover Rumors Circulating About GE

International Game Technology = Wins Big Contract From Svenska Spel in Sweden

WiLAN = Court of Appeals Grants WiLAN Positive Rulings In Case Against Ericsson

Gilead Sciences = Hearing Takeover Rumors Circulating

Juno = Hearing Juno Takeover Rumors Circulating

Fusion Telecommunications = Awarded 3-year $100K For Managed Cloud Services

Teva Pharmaceutical = Receives FDA Approval For Vantrela ER

EPAM Systems = Lands Giant UBS Multi-year Agreement Valued At Over $300 Million

Tutor Perini Building = Receives Notice of Intent To Award a $1.37 Billion Contract From Los Angeles County

Amicus Therapeutics = Hearing Takeover Rumors Circulating

CEMEX = Trump Build That Wall Play

Iridium Communications = Announces Successful First Launch For Space-Based ADS-B Network

Applied Optoelectronics = Play On Switch From Copper To Optical Interconnect Inside Datacenters

3D Systems = Expands its Virtual Surgical Planning Service to Include Cranial Applications


Trading Lessons

Mainstream Financial News


Depomed Inc Said To Have Received One Bid

Follow Us on StockTwits

January 6, 2017: Depomed Inc said to have received one bid according to reports in the mainstream financial media.
Recent mainstream media commentary on potential sale of Depomed:

– On Dec 31st KKR remains interested in acquiring Depomed – NY Post

– One analyst cited expects a deal would value DEPO at $25/shr or $1.5 billion

– On Dec 6th Earlier strength attributed to Spanish press report that Novartis is working on a bid

– On Dec 5th Interest from Horizon reportedly has waned

January 2, 2017: KKR remains interested in acquiring Depomed according to an article in the NY Post. Source:

December 13, 2016: Roth Capital reiterates a Buy rating on Depomed, and sets a price target of $27.

December 12, 2016: Piper Jaffray/Simmons cuts Depomed Inc to an Underweight rating from Neutral, and sets price target at $14.

December 7, 2016: The mainstream media is reporting that Purdue Pharma executive said that Depomed is ‘clearly’ on the radar as Purdue considers M&A; however, company said there is nothing to confirm or deny at the moment.

December 6, 2016: Hearings rumors circulating that Novartis may be working on a bid for Depomed. The source of the rumors appears to be coming from this Spanish press report. You can use Google Translate to translate the webpage into english but here’s what I’ve been able to translate:

“Joe Jimenez, president of Novartis, said last Sunday that it has between $2 billion and $5 billion to buy companies. Depomed would be the chosen one.”

Depomed Stock Chart

The Finviz screener settings used to find Depomed are: Forward P/E Under 20, EPS growth past 5 years Over 30%, Sales growth past 5 years Over 30%, Debt/Equity Low (<0.1), Gross Margin High (>50%), RSI (14) Not Overbought (<50)

Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. In addition to its ability to develop and commercialize new drugs, Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. We have licensed Acuform technology to six pharmaceutical partners, and the technology is currently being used in four marketed drugs, including NUCYNTA ER and Gralise. The company’s strategy is to continue to identify, license and develop new products that offer enhanced therapeutic options patient populations that may be underserved by existing therapies.


Trading The News: Depomed In The News